| Cystic Fibrosis |
1 |
1 |
| Lung |
0 |
0.72 |
| Lung Transplantation |
0 |
0.57 |
| Renal Failure |
0 |
0.33 |
| Child |
0 |
0.3 |
| Chronic Kidney Disease |
0 |
0.28 |
| Cardiomyopathy |
0 |
0.27 |
| Heart Failure (HF) |
0 |
0.27 |
| Revenue and Practice Management |
0 |
0.27 |
| End-Stage Renal Disease |
0 |
0.26 |
| Airway |
0 |
0.24 |
| Canada |
0 |
0.24 |
| Transplantation |
0 |
0.24 |
| Genomic Medicine |
0 |
0.21 |
| COVID-19 |
0 |
0.2 |
| Heart Transplantation |
0 |
0.2 |
| Kidney Transplantation |
0 |
0.2 |
| Osteoporosis |
0 |
0.2 |
| Newborn |
0 |
0.18 |
| Liver Transplantation |
0 |
0.16 |
| Genetic Disorders |
0 |
0.13 |
| Board Certification |
0 |
0.12 |
| Fungal Infection |
0 |
0.12 |
| Genetics |
0 |
0.12 |
| Geriatrics |
0 |
0.12 |
| HIV Infection |
0 |
0.12 |
| Hospital |
0 |
0.12 |
| Insurance |
0 |
0.12 |
| Kidney |
0 |
0.12 |
| Nutrition |
0 |
0.12 |
| Pandemic |
0 |
0.12 |
| Quality of Life |
0 |
0.12 |
| Antibiotics |
0 |
0.08 |
| Liver Disease |
0 |
0.08 |
| Wound Management |
0 |
0.08 |
| Antifungal |
0 |
0.06 |
| Blood |
0 |
0.06 |
| Body Mass Index |
0 |
0.06 |
| Caregiver |
0 |
0.06 |
| Cough |
0 |
0.06 |
| Disease Management |
0 |
0.06 |
| Drug Interaction |
0 |
0.06 |
| Europe |
0 |
0.06 |
| Failure to Thrive |
0 |
0.06 |
| Forced Expiratory Volume in One Second |
0 |
0.06 |
| Gland |
0 |
0.06 |
| Heart |
0 |
0.06 |
| Injury |
0 |
0.06 |
| Isolation |
0 |
0.06 |
| Liver |
0 |
0.06 |
| Malabsorption |
0 |
0.06 |
| Malnutrition |
0 |
0.06 |
| Manipulation |
0 |
0.06 |
| Medicare |
0 |
0.06 |
| Ohio |
0 |
0.06 |
| Osteopenia |
0 |
0.06 |
| Pancreas |
0 |
0.06 |
| Premature Infant |
0 |
0.06 |
| Preventive Screening |
0 |
0.06 |
| Prophylaxis |
0 |
0.06 |
| Pseudomonas Aeruginosa Infection |
0 |
0.06 |
| Psychosocial |
0 |
0.06 |
| Sleep |
0 |
0.06 |
| Thorax |
0 |
0.06 |
| Tissue |
0 |
0.06 |
| Washington |
0 |
0.06 |